20 May 2013
Keywords: cash, shortfall, delays, trial, novacea, aq4n, drugmaker
Article | 14 January 2008
US drugmaker Novacea has decided to scale back on its clinical
development activities for AQ4N (banoxantrone), an investigational
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 January 2008
7 January 2008
© 2013 thepharmaletter.com